



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Hitesh Mistry, PhD  
 Eliana Vasquez Osorio, PhD  
*Division of Cancer Science  
 University of Manchester  
 Manchester, United Kingdom*

Alan McWilliam, PhD  
 Ananya Choudhury, PhD  
*Division of Cancer Science  
 University of Manchester  
 Manchester, United Kingdom*  
*Christie Medical Physics & Engineering  
 The Christie NHS Foundation Trust  
 Manchester, United Kingdom*

Marianne Aznar, PhD  
 Marcel van Herk, PhD  
 Andrew Green, PhD  
*Division of Cancer Science  
 University of Manchester  
 Manchester, United Kingdom*

<https://doi.org/10.1016/j.ijrobp.2021.10.154>

## References

- Shortall J, Palma G, Mistry H, et al. Flogging a dead salmon? Reduced dose posterior to prostate correlates with increased PSA progression in voxel-based analysis of 3 randomized phase 3 trials. *Int J Radiat Oncol Biol Phys* 2021;110:696–699.
- Marcello M, Denham JW, Kennedy A, et al. Reduced dose posterior to prostate correlates with increased PSA progression in voxel-based analysis of 3 randomised phase 3 trials. *Int J Radiat Oncol Biol Phys* 2020;108:1304–1318.
- Ebert MA, Marcello M, Haworth A, et al. In regard to Shortall et al. *Int J Radiat Oncol Biol Phys* 2022;112:831–833.
- Bennett C, Miller M, Wolford G. Neural correlates of interspecies perspective taking in the post-mortem Atlantic Salmon: An argument for multiple comparisons correction. *Neuroimage* 2009;47: S125.
- Witte MG, Heemsbergen WD, Bohoslavsky N, et al. Relating dose outside the prostate with freedom from failure in the Dutch trial 68 Gy vs. 78 Gy. *Radiat Oncol Biol Phys* 2010;77:131–138.
- Chen C, Witte M, Heemsbergen W, van Herk M. Multiple comparisons permutation test for image based data mining in radiotherapy. *Radiat Oncol* 2013;8:293.
- Green A, Vasquez Osorio E, Aznar MC, McWilliam A, van Herk M. Image-based data mining using per-voxel Cox regression. *Front Oncol* 2020;10:1178.
- Cella L, Monti S, Xu T, et al. Probing thoracic dose patterns associated to pericardial effusion and mortality in patients treated with photons and protons for locally advanced non-small-cell lung cancer. *Radiother Oncol* 2021;160:148–158.
- McWilliam A, Kennedy J, Hodgson C, Osorio EV, Faivre-Finn C, van Herk M. Radiation dose to heart base linked with poorer survival in lung cancer patients. *Eur J Cancer* 2017;85:106–113.
- van Herk M. Errors and margins in radiotherapy. *Semin Radiat Oncol* 2004;14:52–64.
- Palma G, Monti S, Cella L. Voxel-based analysis in radiation oncology: A methodological cookbook. *Phys Med* 2020;69:192–204.

## Radiation Recall After COVID-19 Vaccine Booster

### In Regard to Soyfer et al.




Three cases of radiation recall phenomenon (RRP) after COVID-19 vaccination have been reported in the *International Journal of Radiation Oncology, Biology, Physics*. All reported cases to date have followed the first or second dose in the vaccination series and have had a 5- to 7-day onset after vaccination. Within our practice, we observed a case of a delayed radiation recall reaction 28 days after the third dose of the Pfizer BioNTech vaccine.

Soyer et al<sup>1</sup> described 2 patients developing RRP dermatitis after their second dose of Pfizer-BioNTech; 1 patient experienced RRP 5 days after their second vaccination and 66 days after their most recent radiation therapy (RT), and the other experienced RRP 6 days after vaccination and 22 days after RT. Stewart and McDowell<sup>2</sup> described RRP dermatitis after the AstraZeneca vector vaccine, with rapid onset 3 hours after the first dose and occurring 6 months after RT. Additional cases have been reported: Afacan et al<sup>3</sup> reported a case of RRP dermatitis 5 days after initial inoculation with Sinovac and 27 months after RT, and Steber et al<sup>4</sup> noted RRP pneumonitis 3 days after initial vaccination with the Moderna mRNA vaccine, approximately 8 months after RT. The SARS-CoV-2 virus itself may induce similar effects: Kurosaki et al, for instance, have reported an RRP pneumonitis coinciding with COVID-19 infection, 3.5 years after initial RT.<sup>5</sup>


Our patient is a 46-year-old female who received 60 Gy (RBE) in 30 fractions of adjuvant proton irradiation (Fig. 1) with concurrent cisplatin for American Joint Committee on Cancer 8 pT1N1 p16 tonsillar squamous cell carcinoma, completing treatment June 14, 2021 (Fig. 2). She previously received Pfizer-BioNTech vaccination on March 5, 2021, and March 26, 2021, and received her booster vaccine on September 9, 2021. On 3-month follow-up in late September, she exhibited minimal toxicity, with only xerostomia and mild thrush noted. She experienced a dermatitis flare on her neck on October 7 (28 days after dose 3) after 1 day of low-grade fever, nausea, vomiting, and joint pain. Skin cultures were negative, and she was diagnosed with radiation dermatitis (Fig. 1b-f). She was begun on a 2-week oral steroid regimen.

Case reports with RRP remain limited, although both dermatitis and pneumonitis have been seen after a range of SARS-CoV-2 vaccinations, timing, and tumor histologies. This case appears to be the first involving RRP after booster vaccination for SARS-CoV-2 and the first report involving proton irradiation, with delayed development of RRP after vaccination.

Disclosures: none.



**Fig. 1.** (a) Radiation treatment plan, 60 Gy (RBE-1.1) in 30 fractions proton radiation, with (b-f) resultant radiation recall phenomenon skin changes noted.



**Fig. 2.** Patient treatment time course.

Daniel K. Ebner, MD, MPH  
Connie S. Geno, APRN, CNP

Daniel J. Ma, MD  
*Department of Radiation Oncology*  
*Mayo Clinic*  
*Rochester, Minnesota*

4. Steber CR, Ponnatapura J, Hughes RT, Farris MK. Rapid development of clinically symptomatic radiation recall pneumonitis immediately following COVID-19 vaccination. *Cureus* 2021;13:e14303.
5. Kuroski H, Utsumi N, Miura K. A case of suspected radiation recall pneumonitis after a COVID-19 infection. *Cureus* 2021;13:e13688.

## Hyperbaric Oxygen for Prevention of Osteoradionecrosis

## References

1. Soyfer V, Gutfeld O, Shamai S, Schlocker A, Merimsky O. COVID-19 vaccine-induced radiation recall phenomenon. *Int J Radiat Oncol Biol Phys* 2021;110:957–961.
2. Stewart R, McDowell L. Radiation Recall Phenomenon Following COVID-19 Vaccination. *Int J Radiat Oncol Biol Phys* 2021;111:835–836.
3. Afacan E, Öğüt B, Üstün P, Şentürk E, Yazıcı O, Adışen E. Radiation recall dermatitis triggered by inactivated COVID-19 vaccine. *Clin Exp Dermatol* 2021;46:1582–1584.

## In Regard to Shaw et al.



*To the Editor:* Randomized controlled trials (RCTs) are a reliable form of scientific evidence and strongly influence

Disclosure: G.L. is the director of a hyperbaric facility that treats patients with late radiation tissue injury.